Esketamine Combined With Pregabalin on CPSP in Spinal Patients.
Unknown statusPhase 2, Phase 3NCT06117917
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic postsurgical pain has become one of the most common complications of surgery. The quality of life will be impacted once the postsurgical patients are combined with persistent pain. What's more, the postsurgical pain may increase other adverse outcomes. It's important to find a better way to keep the postsurgical patients away from postoperative pain. Esketamine and pregabalin have become potentially effective drugs on CPSP.
Study details
- Official title
- Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients Undergoing Primary Spinal Tumor Surgery.
- Conditions
- Esketamine
- Pregabaline
- Chronic Post Operative Pain
- Interventions
- Drug: S-ketamine and pregabalin
- Drug: Normal saline and placebo capsule
- Sponsor
- Beijing Tiantan Hospital
- Start date
- 2023-11-10
- Primary completion
- 2024-05-31
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient undergoing elective primary spinal tumor surgery; * Ages between 18 and 65 years old; * American Society of Anaesthesiology (ASA) status I-III; * Signed informed consent. Exclusion Criteria: * Previous adverse reaction to ketamine, s-ketamine or pregabalin; * Patients with a diagnosed history of severe chronic pain; * Patients with long-term analgesic treatment(gabapentin/opioids/ketamine); * Patients with aphasia or inability to cooperate with the pain assessments; * Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure); * Patients with a diagnosed history of psychiatric disorder; * Patients treated with gabapentin/pregabalin in the last three months; * Drug abuse; * Body mass index (BMI) \> 35 kg/m2 ; * Pregnancy or lactation.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06117917